Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Nikolaos Trikalinos
Advertisement
Articles by Nikolaos Trikalinos
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
3
COA Backs 340B Payment Cut in 2027 Final Rules, Warns of Physician Cuts
4
Moving Past Empiric Chemotherapy in Platinum-Sensitive Ovarian Cancer
5